D
Dongfang Wu
Researcher at Wuhan University
Publications - 8
Citations - 1841
Dongfang Wu is an academic researcher from Wuhan University. The author has contributed to research in topics: Internal medicine & Adverse effect. The author has an hindex of 3, co-authored 5 publications receiving 1456 citations.
Papers
More filters
Journal ArticleDOI
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
Ying Hui Jin,Lin Cai,Zhen Shun Cheng,Hong Cheng,Tong Deng,Tong Deng,Yi Pin Fan,Cheng Fang,Di Huang,Lu Qi Huang,Qiao Huang,Yong Han,Bo Hu,Fen Hu,Bing Hui Li,Bing Hui Li,Yi Rong Li,Ke Liang,Likai Lin,Li Sha Luo,Jing Ma,Lin Lu Ma,Zhi Yong Peng,Yunbao Pan,Zhen Yu Pan,Xue Qun Ren,Hui Min Sun,Ying Wang,Yun Yun Wang,Hong Weng,Chao Jie Wei,Dongfang Wu,Jian Xia,Yong Xiong,Haibo Xu,Xiao Mei Yao,Yu Feng Yuan,Tai Sheng Ye,Xiaochun Zhang,Ying Wen Zhang,Yin Gao Zhang,Hua Min Zhang,Yan Zhao,Ming Juan Zhao,Hao Zi,Hao Zi,Xian Tao Zeng,Yong Yan Wang,Xinghuan Wang +48 more
TL;DR: This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.
Journal ArticleDOI
Attitudes and perceptions regarding antimicrobial use and resistance among medical students in Central China
TL;DR: Investigation of the attitudes and perceptions of senior medical students regarding antimicrobial use and resistance in Central China found that curriculum system in Chinese institutions should make an effort to optimize curriculum system to make the authors' future doctors better prepared for antimicrobial stewardship and prudent antimicrobial prescribing.
Journal ArticleDOI
Medication Patterns and Disease Progression Among 165 Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective, Observational Study
Feng Sun,Hao Kou,Shengfeng Wang,Lu Yun,Houyu Zhao,Li Wenjing,Qingxin Zhou,Qiaoli Jiang,Yinchu Cheng,Kun Yang,Lin Zhuo,Yang Xu,Dongfang Wu,Siyan Zhan,Hong Cheng +14 more
TL;DR: Medication patterns for COVID-19 were diverse but generally complied with the existing guideline, and a potential therapeutic time window of 72 hours might exist in non-severe patients, especially for antiviral drugs.
Journal ArticleDOI
An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients
Feng Sun,Hao Kou,Shengfeng Wang,Lu Yun,Houyu Zhao,Li Wenjing,Qingxin Zhou,Qiaoli Jiang,Yinchu Cheng,Kun Yang,Lin Zhuo,Yang Xu,Dongfang Wu,Siyan Zhan,Hong Cheng +14 more
TL;DR: Wu et al. as mentioned in this paper conducted a case series study of 165 consecutive hospitalized COVID-19 patients who were followed up until March 25, 2020, from a designated hospital in Wuhan, China, where patients were grouped by a baseline degree of severity: non-severe and severe.
Journal ArticleDOI
Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice.
TL;DR: High-level PON1 improved dysfunctional HDL and alleviated the development of atherosclerosis in Scarb1-/- mice, suggesting that Pon1 represents a promising target of HDL-based therapeutic strategy for HDL-related atherosclerotic cardiovascular disease.